Treatment outcome and relapse with short-term oral terbinafine (250 mg/day) in tinea pedis. 2005

Iwao Takiuchi, and Nobuaki Morishita, and Taizo Hamaguchi, and Junya Ninomiya, and Ryota Higuchi
Department of Dermatology, Showa University Fujigaoka Hospital, Kanagawa, Japan.

A total of 168 patients with tinea pedis, but without onychomycosis, were treated with 1 cycle of terbinafine (TBF) (1 cycle: defined as 250 mg/day for 1 week). KOH preparation for direct microscopy was performed 4, 8 and 12 weeks after starting therapy to determine if testing was positive for tinea. Patients with no negative results on KOH examination or no evidence of obvious clinical improvement at 8 weeks, another cycle of the therapy was prescribed. The "cure", "no cure", "dropout", and "discontinuation/unevaluable" rates were 89.3%, 4.8%, 4.8% and 1.2%, respectively. The number of cycles required for cure in the plantar type was 1 cycle in 65.9% and 2 cycles in 54.5% of cases; in the interdigital type, 1 cycle in 79.1% and 2 cycles in 20.9% of cases; and mixed type, 1 cycle in 29.1% and 2 cycles in 60.9% cases. Among patients who were followed for at least 3 years after cure, the relapse rates were about 10% each year: 1 year, 11.3%; 2 years, 8.9%; and 3 years, 11.2%. The relapse rate of about 10% each year over a 3-year period suggests that reinfection may be likely.

UI MeSH Term Description Entries
D009281 Naphthalenes Two-ring crystalline hydrocarbons isolated from coal tar. They are used as intermediates in chemical synthesis, as insect repellents, fungicides, lubricants, preservatives, and, formerly, as topical antiseptics.
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006878 Hydroxides Inorganic compounds that contain the OH- group.
D000077291 Terbinafine A naphthalene derivative that inhibits fungal SQUALENE EPOXIDASE and is used to treat DERMATOMYCOSES of the skin and nails. (E)-N-(6,6-Dimethyl-2-heptenynyl)-N-methyl-1-naphthalenementhamin hydrochloride,DA 5505,Lamisil,SF 86-327,SF-86-327,TDT-067,Terbinafine Hydrochloride,Terbinafine, (Z)-,Terbinafine, (Z)-isomer,SF 86 327,SF 86327,SF86327,TDT 067,TDT067
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics
D014008 Tinea Pedis Dermatological pruritic lesion in the feet, caused by Trichophyton rubrum, T. mentagrophytes, or Epidermophyton floccosum. Athlete's Foot,Athlete Foot,Athletes Foot
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Iwao Takiuchi, and Nobuaki Morishita, and Taizo Hamaguchi, and Junya Ninomiya, and Ryota Higuchi
April 1994, The British journal of dermatology,
Iwao Takiuchi, and Nobuaki Morishita, and Taizo Hamaguchi, and Junya Ninomiya, and Ryota Higuchi
January 2002, Nihon Ishinkin Gakkai zasshi = Japanese journal of medical mycology,
Iwao Takiuchi, and Nobuaki Morishita, and Taizo Hamaguchi, and Junya Ninomiya, and Ryota Higuchi
October 1998, The British journal of dermatology,
Iwao Takiuchi, and Nobuaki Morishita, and Taizo Hamaguchi, and Junya Ninomiya, and Ryota Higuchi
April 1995, The British journal of dermatology,
Iwao Takiuchi, and Nobuaki Morishita, and Taizo Hamaguchi, and Junya Ninomiya, and Ryota Higuchi
January 2003, Nihon Ishinkin Gakkai zasshi = Japanese journal of medical mycology,
Iwao Takiuchi, and Nobuaki Morishita, and Taizo Hamaguchi, and Junya Ninomiya, and Ryota Higuchi
February 1998, International journal of dermatology,
Iwao Takiuchi, and Nobuaki Morishita, and Taizo Hamaguchi, and Junya Ninomiya, and Ryota Higuchi
August 1996, International journal of dermatology,
Iwao Takiuchi, and Nobuaki Morishita, and Taizo Hamaguchi, and Junya Ninomiya, and Ryota Higuchi
July 2001, Cutis,
Iwao Takiuchi, and Nobuaki Morishita, and Taizo Hamaguchi, and Junya Ninomiya, and Ryota Higuchi
February 1995, Journal of the American Academy of Dermatology,
Iwao Takiuchi, and Nobuaki Morishita, and Taizo Hamaguchi, and Junya Ninomiya, and Ryota Higuchi
September 2014, Mycoses,
Copied contents to your clipboard!